Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study

Diabetes Research and Clinical Practice

Volumn 90, Issue 2, 2010, Pages 182-190

  Banerji, M A ^a   Purkayastha, D ^b   Francis, B H ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Mild renal impairment; Safety; Thiazolidinediones; Vildagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINALYSIS; VITAL SIGN;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FUNCTION TESTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; RETROSPECTIVE STUDIES; SAFETY; THIAZOLIDINEDIONES;

EID: 77957749759     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.06.022     Document Type: Article

References (32)

1. United States Renal Data System USRDS 2007 Annual Data Report 2007, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD.
2. National Institute of Diabetes and Digestive and Kidney Diseases National Diabetes Statistics, 2007 2008, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD.
3. Ahrén B., Landin-Olsson M., Jansson P.-A., Svenson M., Holmes D., Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:2078-2084.
4. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Saylan M., Dunning B.E., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:4888-4894.
5. He Y.-L., Sadler M.B., Sabo R., Balez S., Wang Y., Howard D., et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007, 46(9):787-802.
6. Dejager S., Razac S., Foley J.E., Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007, 39:218-223.
7. Rosenstock J., Baron M.A., Dejager S., Mills D., Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007, 30:217-223.
8. 1c over one year in drug-naive patients with type 2 diabetes. Diabet Med 2007, 24:955-961.
9. Pi-Sunyer F.X., Schweizer A., Mills D., Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138.
10. Garber A.J., Schweizer A., Baron M.A., Rochotte E., Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9:166-174.
11. Bosi E., Camisasca R.P., Collober C., Garber A.J. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30:890-893.
12. Rosenstock J., Baron M.A., Camisasca R.P., Cressier F., Couturier A., Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:175-185.
13. Ahrén B., Gomis R., Standl E., Mills D., Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase-IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880.
14. Pratley R.E., Rosenstock J., Pi-Sunyer F.X., Banerji M.A., Schweizer A., Couturier A., et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007, 30(12):3017.
15. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008, 31:173-175.
16. Stumvoll M., Haring H.-U. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002, 34:217-224.
17. Agrawal A., Sautter M.C., Jones N.P. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther 2003, 25(11):1764-2754.
18. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941-2948.
19. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
20. Masakazu H., Akizuki M. Which hypoglycemic agents to use in type 2 diabetic subjects with CKD and how?. Nephrol Dial Transplant 2009, 24(2):338-341.
21. Blonde L., Dagogo-Jack S., Banerji M.A., Pratley R.E., Marcellari A., Braceras R., et al. Vildagliptin is as effective as thiazolidinediones as add-on therapy in patients failing on metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab 2009, 11:978-986.
22. Rigalleau V., Lasseur C., Perlemoine C., Barthe N., Raffaitin C., Liu C., et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of diet in renal disease study equation?. Diabetes Care 2005, 28(4):838-843.
23. Williams-Herman D., Round E., Swern S.A., Musser B., Davies J.M., Stein P.P., et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008, 8:14.
24. Bolli G., Dotta F., Rochotte E., Cohen S.E. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008, 10(1):82-90.
25. Filozof C., Schwartz S., Foley J.E. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes 2010, 1(1):19-26.
26. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week double-blind, randomized trial. Diabetes Obes Metab 2009, 11:804-812.
27. Charbonnel B.H., Matthews D.R., Schernthaner G., Hanefeld M., Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005, 22:399-405. QUARTET Study Group.
28. Matthews D.R., Charbonnel B.H., Hanefeld M., Brunetti P., Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005, 21:167-174.
29. Ligueros-Saylan M., Foley J.E., Schweizer A., Couturier A., Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010, 12(6):495-509.
30. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
31. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989, 18:103-121.
32. Fischer J.A., Lees J.H., Newman Hypoglycemia in hospitalized patients. Causes and outcomes. N Engl J Med 1986, 315:1245-1250.